Dexmedetomidine for Improved Pain Relief and Recovery in Spine Surgery
CompletedNot applicableNCT06685081
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Chronic low back pain (CLBP) is a prevalent condition causing significant pain, disability, and reduced quality of life. While various treatments like exercise, NSAIDs, and spinal manipulation are recommended, their effectiveness is limited. Epidural steroid injections can provide short-term relief but may not be cost-effective and have associated risks. Dexmedetomidine (DXM) is a selective α2-adrenergic agonist with analgesic properties. It has been used as an adjuvant to anesthetics and analgesics to enhance pain relief and reduce opioid consumption. Using DXM in conjunction with local anesthetics for regional blocks has shown promising results in improving analgesia and functional outcomes.
Study details
- Official title
- Optimal-dose of Dexmedetomidine as Adjuvant to Epidural Local Anesthetic/Steroid Injectate to Improve Pain and Quality of Waking in Patients With Chronic Low Back Pain: A Randomized Case-control Study
- Conditions
- Interventions
- Drug: Dexmedetomidine
- Drug: Dexmedetomidine
- Drug: Dexmedetomidine
- Drug: Dexmedetomidine
- Drug: lidocaine and triamcinolone
- Sponsor
- Menoufia University
- Start date
- 2024-07-01
- Primary completion
- 2024-10-15
- Sex
- All
- Age range
- from 35 Years to 75 Years
- Results posted
- No results posted in this snapshot
- Countries
- Egypt
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients who had Chronic Lower Back pain defined as persistent pain for more than 6 weeks with manifest affection of daily activities; * Patients who had Chronic Lower Back pain defined as persistent pain for more than 6 weeks with manifest affection of quality of walking and life; * Patients who had Chronic Lower Back pain defined as persistent pain for more than 6 weeks maintained on systemic analgesics; * Patients who were free of exclusion criteria were enrolled in the study. Exclusion Criteria: * The presence of osteolytic vertebral lesions; * The Presence of previous surgical intervention; * The presence of allergy to the studied drugs; * Patients of ASA grade \>II.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06685081